{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:04:54Z","timestamp":1784909094949,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ymgmr.2026.101310","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T22:09:34Z","timestamp":1775945374000},"page":"101310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical experience with Pegvaliase in phenylketonuria: A retrospective chart review of outcomes, safety, and dosing patterns"],"prefix":"10.1016","volume":"47","author":[{"given":"Jariya","family":"Upadia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kea","family":"Crivelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2026.101310_bb0005","first-page":"1054","article-title":"Excretion of phenylpyruvic acid in urine as a metabolicnomaly in connection with imbecility","volume":"8","author":"F\u00f8lling","year":"1934","journal-title":"Nord. Med. Tidskr."},{"issue":"23","key":"10.1016\/j.ymgmr.2026.101310_bb0010","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJM198012043032305","article-title":"Phenylketonuria: epitome of human biochemical genetics (first of two parts)","volume":"303","author":"Scriver","year":"1980","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgmr.2026.101310_bb0015","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1007\/PL00014369","article-title":"Comments on the neuropathology of phenylketonuria","volume":"159","author":"Dyer","year":"2000","journal-title":"Eur. J. Pediatr."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgmr.2026.101310_bb0020","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ymgme.2009.10.005","article-title":"White matter pathology in phenylketonuria","volume":"99","author":"Anderson","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2026.101310_bb0025","series-title":"Robert Guthrie - The PKU Story: A Crusade against Mental Retardation","author":"Koch","year":"1997"},{"issue":"1","key":"10.1016\/j.ymgmr.2026.101310_bb0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0028-3932(01)00078-1","article-title":"Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations","volume":"40","author":"Huijbregts","year":"2002","journal-title":"Neuropsychologia"},{"issue":"2","key":"10.1016\/j.ymgmr.2026.101310_bb0035","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/gim.2013.157","article-title":"Phenylalanine hydroxylase deficiency: diagnosis and management guideline","volume":"16","author":"Vockley","year":"2014","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ymgmr.2026.101310_bb0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10545-008-0940-8","article-title":"Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria","volume":"32","author":"Trefz","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2026.101310_bb0045","article-title":"Maximal dietary responsiveness after tetrahydrobiopterin (BH4) in 19 phenylalanine hydroxylase deficiency patients: what super-responders can expect","volume":"38","author":"Upadia","year":"2024","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"23","key":"10.1016\/j.ymgmr.2026.101310_bb0050","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.3390\/nu14234960","article-title":"Complications of the low phenylalanine diet for patients with phenylketonuria and the benefits of increased natural protein","volume":"14","author":"McWhorter","year":"2022","journal-title":"Nutrients"},{"issue":"18","key":"10.1016\/j.ymgmr.2026.101310_bb0055","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.3390\/nu16183119","article-title":"Factors affecting adherence to a low phenylalanine diet in patients with phenylketonuria: a systematic review","volume":"16","author":"Yagudina","year":"2024","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.ymgmr.2026.101310_bb0060","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ymgme.2018.06.002","article-title":"Phenylalanine ammonia lyase (PAL): from discovery to enzyme substitution therapy for phenylketonuria","volume":"124","author":"Levy","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2026.101310_bb0065","first-page":"101084","article-title":"Pegvaliase for the treatment of phenylketonuria: final results of a long-term phase 3 clinical trial program","volume":"39","author":"Harding","year":"2024","journal-title":"Mol. Genet Metab. Rep."},{"key":"10.1016\/j.ymgmr.2026.101310_bb0070","series-title":"PALYNZIQ (Pegvaliase-Pqpz) Injection, for Subcutaneous Use","year":"2026"},{"issue":"1","key":"10.1016\/j.ymgmr.2026.101310_bb0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymgme.2018.03.006","article-title":"Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM)","volume":"124","author":"Thomas","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgmr.2026.101310_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2025.101405","article-title":"Pegvaliase therapy for phenylketonuria: real-world safety, efficacy, and medication access outcomes in a pharmacist-led pegvaliase program","volume":"27","author":"Shrestha","year":"2025","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2026.101310_bb0085","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ebiom.2018.10.038","article-title":"Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials","volume":"37","author":"Gupta","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymgmr.2026.101310_bb0090","doi-asserted-by":"crossref","first-page":"e2014009","DOI":"10.4178\/epih\/e2014009","article-title":"Dietary assessment methods in epidemiologic studies","volume":"36","author":"Shim","year":"2014","journal-title":"Epidemiol. Health"},{"issue":"1\u20132","key":"10.1016\/j.ymgmr.2026.101310_bb0095","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ymgme.2019.05.006","article-title":"Pegvaliase: immunological profile and recommendations for the clinical management of hypersensitivity reactions in patients with phenylketonuria treated with this enzyme substitution therapy","volume":"128","author":"Hausmann","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgmr.2026.101310_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108151","article-title":"Pegvaliase therapy for phenylketonuria: real-world case series and clinical insights","volume":"142","author":"Scala","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2026.101310_bb0105","doi-asserted-by":"crossref","DOI":"10.1177\/1177392819857089","article-title":"A comprehensive review of pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria","volume":"13","author":"Hydery","year":"2019","journal-title":"Drug Target Insights"}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426926000224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426926000224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:17:46Z","timestamp":1784906266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426926000224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":21,"alternative-id":["S2214426926000224"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2026.101310","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical experience with Pegvaliase in phenylketonuria: A retrospective chart review of outcomes, safety, and dosing patterns","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2026.101310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101310"}}